MRVI vs. CTLT, ROIV, ELAN, ASND, LEGN, CERE, VKTX, ITCI, JAZZ, and BPMC
Should you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Catalent (CTLT), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Catalent (NYSE:CTLT) and Maravai LifeSciences (NASDAQ:MRVI) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking.
Catalent presently has a consensus target price of $53.14, indicating a potential downside of 1.22%. Maravai LifeSciences has a consensus target price of $11.44, indicating a potential upside of 32.00%. Given Catalent's stronger consensus rating and higher possible upside, analysts plainly believe Maravai LifeSciences is more favorable than Catalent.
Catalent has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500.
Catalent has a net margin of -26.61% compared to Catalent's net margin of -47.81%. Maravai LifeSciences' return on equity of -2.73% beat Catalent's return on equity.
In the previous week, Maravai LifeSciences had 2 more articles in the media than Catalent. MarketBeat recorded 12 mentions for Maravai LifeSciences and 10 mentions for Catalent. Maravai LifeSciences' average media sentiment score of 0.74 beat Catalent's score of 0.68 indicating that Catalent is being referred to more favorably in the media.
Maravai LifeSciences has lower revenue, but higher earnings than Catalent. Catalent is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.
50.3% of Maravai LifeSciences shares are held by institutional investors. 0.3% of Catalent shares are held by insiders. Comparatively, 0.6% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Catalent received 582 more outperform votes than Maravai LifeSciences when rated by MarketBeat users. However, 67.44% of users gave Maravai LifeSciences an outperform vote while only 59.15% of users gave Catalent an outperform vote.
Summary
Maravai LifeSciences beats Catalent on 11 of the 18 factors compared between the two stocks.
Get Maravai LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Maravai LifeSciences Competitors List
Related Companies and Tools
